

Bringing Better Health Within Reach: Hikma's journey to become the Partner of choice in MENA

London, 29 April 2024 – When Hikma was founded in 1978, its central purpose was to fill a profound gap in access to high-quality affordable medicines across the Middle East and North Africa (MENA) region. While the scope and reach of Hikma's operations has expanded since then, improving patients' access to health remains our central purpose nearly 50 years later.

2023 was an exceptional year for Hikma in which we became the second largest pharmaceutical company in the MENA region by sales¹. We significantly expanded the availability of essential treatments in the region and grew our extensive network of global partners through strategic partnerships, including with Guardant Health, Rakuten Medical, SK Biopharmaceuticals, Celltrion, Junshi and Cosmo.

Our MENA business development team had a record year in deal signing - adding more than 25 assets to our portfolio through strategic partnerships. These partnerships brought innovative interventions for cancer, autoimmune diseases, and CNS amongst other conditions to MENA - fundamentally improving access to world-class diagnostics and treatments and ultimately the quality of life of patients in the region. We have firmly positioned ourselves as a partner of choice for multinational companies aligned with our vision of shaping a healthier world and looking to expand access to new technologies and health innovations in the region.

This is made possible by Hikma's unparalleled access, deep understanding, and connectivity with health communities in each country where we operate. As we continue to enhance our leading position in MENA, we remain focused on our duty and responsibility to bring new treatments, access and innovative solutions into the region. Our scale, breadth of offering, strong commercial capabilities, and our deep-rooted ties to MENA help us deliver on our goal of putting better health within reach for patients across the region.

Over the coming weeks, we will explore in a series of posts how we are evolving our business as the partner of choice for international companies that cover wider healthcare solutions who are looking to expand in MENA – a region with high unmet needs and wealth of opportunities.

-- ENDS --

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

¹ Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.



©2024 Hikma Pharmaceuticals PLC. All rights reserved.

Forward-looking statements

Hikma cautions shareholders that any forward-looking statements or projections made by Hikma, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those risk factors described in the “Principal risks and uncertainties” section in Hikma’s latest Annual Report. Where included, such statements have been made by or on behalf of Hikma in good faith based upon the knowledge and information available to the Directors on the date of this announcement. Accordingly, no assurance can be given that any particular expectation will be met and Hikma's shareholders are cautioned not to place undue reliance on any forward-looking statements. Other than in accordance with its legal or regulatory obligations (including under the UK Market Abuse Regulation and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake to update any forward-looking statements contained in this announcement to reflect any changes in events, conditions or circumstances on which any such statement is based or to correct any inaccuracies which may become apparent in any such forward-looking statements.